Circulating miR-200 family as predictive markers during systemic therapy of metastatic breast cancer.
Chiara FischerThomas Maximilian DeutschManuel FeisstNathalie RippingerFabian RiedelAndreas D HartkopfSara Y BruckerChristoph DomschkeCarlo FremdLaura MichelBarbara BurwinkelAndreas SchneeweissAndrey TurchinovichMarkus WallwienerPublished in: Archives of gynecology and obstetrics (2022)
Circulating miR-200s were differentially expressed among patients with late and/or early relapse. 4 of 5 members of the miR-200 family predicted significantly early relapse after systemic treatment. Our results encourage the use of circulating miR-200s as valuable prognostic biomarkers during metastatic breast cancer therapy.